The read at a glance
Computed from the FY2025 annual filing. Full history and the components behind each score are in the app.
- Distress risk · Altman Z-Score 1.26 — grey zone — between safe and distressedWatch
- Earnings quality 86/100 — accruals in line with cashOK
Where the revenue comes from
Fiscal 2025, as IONIS PHARMACEUTICALS INC reports it. History and quarterly detail are in the app.
- Research And Development Revenue$507.9M
- Collaborative Agreement Revenue$465.8M
- Commercial$435.8M
- Royalty$285.5M
- Spinraza Royalties$212.3M
Leadership changes
From IONIS PHARMACEUTICALS INC's own filings, the day they're filed.
- Peter N. Reikes · Director · appointmenteff. 2026-06-04
- Ludwig N. Hantson · chief executive officer · appointmenteff. 2026-06-04
- Joseph H. Wender · Directors · departureeff. 2026-03-03
Latest filings
- 8-K · Company announcement2026-06-12
- 8-K · Company announcement2026-06-08
- 8-K · Company announcement2026-05-28
- 10-Q · Quarterly report2026-04-29
- 8-K · Company announcement2026-04-29
In the full recordFree for 14 days
- The filings, readable — with what changed vs the prior year highlighted🔒
- Full financial statements, industry-aware, every figure source-linked🔒
- Forensic score history & components — the trend, not one year🔒
- Ownership: insider buys/sells, clusters, activist stakes🔒
- Ana — ask anything about IONIS PHARMACEUTICALS INC, every answer cited🔒
- The Intelligence Brief — added when IONIS PHARMACEUTICALS INC's brief passes our SEC-figure check🔒
Every figure links to the filing it came from, and analysis whose figures don't match SEC data is rejected before publication.
14-day free trial, no credit card. For research purposes only; not investment advice.